Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape.

Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, Adam V. · 2022

Read Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. by Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, Adam V. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9166526.txt.

Introduction

Wu and co-authors review how hypoxia-inducible factors help tumors escape immune attack. Low oxygen is common inside tumors and weakens killer T cells. It also draws in regulatory T cells that calm immune responses. Two factors, HIF1A and HIF2A, sit at the center of this escape.

The review traces the signal chains each factor sets off. One chain raises the PD-1 and PD-L1 checkpoint that brakes T cells. Another helps tumors hide from natural killer cells. HIF2A also recruits mast cells that flood the tumor with calming signals. Long noncoding RNAs add yet another layer of escape. The authors argue that blocking HIF could sharpen tumor immunotherapy.

Catalog record

CREATORWu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, Adam V.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE91 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9166526

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape By Qinghua Wu, Li You, Eugenie Nepovimova, Zbynek Heger, Wenda Wu, Kamil Kuca, Vojtech Adam Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-022-01292-6 ABSTRACT Abstract Hypoxia, a common feature of the tumor microenvironment in various types of cancers, weakens cytotoxic T cell function and causes recruitment of regulatory T cells, thereby reducing tumoral immunogenicity. Studies have demonstrated that hypoxia and hypoxia-inducible factors (HIFs) 1 and 2 alpha (HIF1A and HIF2A) are involved in tumor immune escape. Under hypoxia, activation of HIF1A induces a series of signaling events, including through programmed death receptor-1/programmed death ligand-1. Moreover, hypoxia triggers shedding of complex class I chain-associated molecules through nitric oxide signaling impairment to disrupt immune surveillance by natural killer cells. The HIF-1-galactose-3-O-sulfotransferase 1-sulfatide axis enhances tumor immune escape via increased tumor cell-platelet binding. HIF2A upregulates stem cell factor expression to recruit tumor-infiltrating mast cells and increase levels of cytokines interleukin-10 and transforming growth factor-β, resulting in an immunosuppressive tumor microenvironment. Additionally, HIF1A upregulates expression of tumor-associated long noncoding RNAs and suppresses immune cell function, enabling tumor immune escape. Overall, elucidating the underlying mechanisms by which HIFs promote evasion of tumor immune surveillance will allow for targeting HIF in tumor treatment. This review discusses the current knowledge of how hypoxia and HIFs facilitate tumor immune escape, with evidence to date implicating HIF1A as a molecular target in such immune escape. This review provides further insight into the mechanism of tumor immune escape, and strategies for tumor immunotherapy are suggested. Keywords: Hypoxia, Hypoxia-inducible factors, Tumor disease, Immunotherapy, Personalized medicine BACKGROUND In general, tumor occurrence is closely related to immune function [1, 2], as low or suppressed immune function increases the risk of tumor incidence [3]. Thus, scientists have proposed the “tumor immune editing” theory with regard to the relationship between tumorigenesis and immunity [4, 5]. According to this theory, the immune system can identify, monitor, and ultimately clear most malignant cells; however, a few malignant cells escape this surveillance and enter an “equilibrium” stage, during which the immune system and cancer cells modulate each other, resulting in no clinical symptoms [6, 7]. Malignant tumor cells have also evolved to bypass this equilibrium, culminating in immune escape [8, 9], which occurs through modifications to both the tumor cells and tumor microenvironment [10]. Knowledge of the mechanisms regulating tumor immune escape will contribute to the development of new strategies for immunotherapy [11]. As various tumor immune escape mechanisms exist in a complex network, comprehensive treatment targeting multiple escape mechanisms appears to be a promising strategy for drug development [12]. Hypoxia is a common feature of the tumor microenvironment in various cancers [13, 14]. In most tumors, the degree of oxygenation is not uniform, and pathological hypoxic states can occur regionally [15]. Rapid tumor cells growth increases oxygen consumption during tumorigenesis, resulting in an intratumoral gradient of oxygen partial pressure [16]. Furthermore, hypoxia and overexpression of hypoxia-inducible factors (HIFs) 1 and 2 alpha (HIF1A and HIF2A) are involved in tumor immune escape and promote tumorigenesis [17–19] (Fig. 1). Under hypoxia, activation of HIFs and their downstream signaling pathways (including CXCR4, M-CSFR, and CD47) regulate the tumor-specific immune response, with production of several immunosuppressive cytokines and growth factors to allow for immune escape and promoted tumor progression [20, 21]. The immunological checkpoint composed of programmed cell death 1/programmed cell death 1 ligand 1 (PD-D1/PD-L1) inhibits T cell activation and proliferation, negatively regulating the cellular immune response and ultimately leading to immune escape [22, 23]. HIFs mediate tumor immune escape in various hypoxic solid tumors [24–26]. For example, HIF1A upregulates the negative immune checkpoint regulator V-set immunoregulatory receptor (VSIR) in colon cancer [27] and increases interleukin (IL)-23 expression in glutamine-deficient macrophages, which may suppress T cell immune function in clear cell renal cell carcinoma (ccRCC) to achieve immune escape [28]. In addition to HIF1A, HIF2A plays a role in the tumor immune escape mechanism: this isoform enhances expression of stem cell factor (SCF) in ccRCC patients, and upregulation of SCF protein expression promotes secretion of transforming growth factor (TGF)-β and IL-10, thereby forming an immunosuppressive tumor microenvironment and escaping tumor immunity [29]. [Figure: The protein structure of HIF1A and HIF2A. HIF1A and HIF2A contain basic helixloop-helix (bHLH) and Par-Arnt-SIM (PAS) transcription factors. And they also have N/C-terminal transactivation domain (N/C-TAD), inhibitory domain (ID), and oxygen-dependent degradation domain (ODD). Their DNA has a high degree of similarity. NLS: nuclear localization signal, pVHL: von Hippel-Lindau protein] Furthermore, tumor-associated long noncoding RNAs (lncRNAs) play pivotal roles in HIF1A pathway regulation and tumor immune escape. Under hypoxia, lncRNAs act as oncogenic HIF1A targets to promote tumor progression in osteosarcoma cells and bladder tumors [30, 31]. Notably, lncRNAs participate in tumor immune escape by influencing regulatory T cells (Tregs) and the PD-L1/PD-1 immune checkpoint to inhibit T cell immune functions [32]. Nevertheless, the underlying mechanism by which hypoxia-related lncRNAs promote immune escape is largely unknown. Indeed, most lncRNA studies have focused on their effects on the proliferation, invasion, and migration of tumors, whereas in-depth evaluation of their effects is required for targeting them clinically [33]. Tumor invasiveness and metastasis are major challenges in cancer treatment [34–36]. HIFs regulate a series of signaling pathways to promote the angiogenesis, metastasis, and invasive abilities of cancer cells [37–39]. Although tumor treatment strategies targeting HIFs have attracted widespread attention [40, 41], resistance is a common challenge, and hypoxia is a major factor that induces tumor chemoresistance [42]. By inducing expression of drug carrier proteins, the hypoxic tumor environment also affects drug transport and cellular drug uptake, further exacerbating resistance to chemotherapy [43]. This review discusses the underlying mechanisms by which hypoxia and HIFs (HIF1A and HIF2A) promote tumor immune escape, as well as the role of HIFs in cancer invasiveness, metastasis, and tumor chemoresistance. In addition, lncRNAs and their potential roles in hypoxic tumor immune escape are discussed. This review expands our understanding of immune escape in tumorigenesis and provides insight into potential novel and more efficient anticancer therapies. TUMOR IMMUNE ESCAPE Tumor immune escape is a phenomenon through which tumor cells escape recognition and attack by the immune system through various mechanisms, enabling their survival and proliferation [44, 45]. Through its immune surveillance function, the immune system recognizes malignant cells as “nonself” and precisely eliminates them, which prevents tumor development [46, 47]. Several immune escape mechanisms, including antigenic deletion, immune inhibition caused by tumor cells, tumor cell leakage, lack of costimulatory signals on the tumor cell surface, and the antiapoptotic effects of tumor cells, have been described thus far [48–50]. Tumor cells inhibit T cell activation through a series of changes (such as loss of antigen expression) to avoid immune surveillance and reduce the time elapsed before growth [51]. Tumor cells also regulate their autoantigenicity through antigen endocytosis or shedding [52]. Mutations in tumor-related genes alter signaling pathways in tumor cells, affecting the biological characteristics of the tumor and its immunogenicity [53, 54]. In general, a tumor antigen presented in the absence of a costimulatory signal will induce antigenic tolerance in the T cells that recognize the antigen [55]. Moreover, tumors produce immunosuppressive molecules, including indoleamine 2,3-dioxygenase 1 and PD-L1, which directly suppress the immune response or recruit

Read the complete text